Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average) (2020 - 2025)

Crinetics Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $94.1 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $94.1 million for Q4 2025, up 16.43% from a year ago — trailing twelve months through Dec 2025 was $94.1 million (up 16.43% YoY), and the annual figure for FY2025 was $94.1 million, up 16.43%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $94.1 million at Crinetics Pharmaceuticals, roughly flat from $94.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CRNX hit a ceiling of $94.2 million in Q3 2025 and a floor of $35.0 million in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $56.8 million (2023), compared with a mean of $64.1 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 7.9% in 2023 and later skyrocketed 46.06% in 2024.
  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $38.4 million in 2021, then surged by 35.24% to $52.0 million in 2022, then rose by 11.71% to $58.1 million in 2023, then surged by 39.11% to $80.8 million in 2024, then rose by 16.43% to $94.1 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $94.1 million (Q4 2025), $94.2 million (Q3 2025), and $93.4 million (Q2 2025) per Business Quant data.